tretinoin and Carcinoma--Transitional-Cell

Previous researches showed that the expression level of E-Cad in most infiltrating cancer cells was reduced or negative. This study explored whether 4HPR restrained the infiltration of bladder cancer cells through regulating the expression of E-Cad. The infiltrating bladder cancer cells T24 were cultured, and then treated by a proper dosage of drug. Their viability was a determined by MTT method. Western blotting and RT-PCR were adopted to detect the changes of E-Cad gene expression at both protein and mRNA levels. Moreover, immunofluorescent staining and confocal fluorescence microscopy were employed for the observation of the expression of E-Cad. The result showed that, at both mRNA and protein levels, the expression level of E-Cad in T24 cells treated by 4HPR was significantly higher than that of control group, while the β-Cat expression was also relocated from the cell nucleus to cytoplasm. Our findings suggested that the regulatory function of 4HPR on infiltration of bladder cancer cells T24 is at least partly achieved by regulating the expression of E-Cad.

Topics: Antineoplastic Agents; Apoptosis; Cadherins; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Tretinoin; Urinary Bladder Neoplasms

Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma, Transitional Cell; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Neoplasms, Multiple Primary; Oxides; Remission Induction; Tretinoin; Urinary Bladder Neoplasms

Topics: Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Drug Therapy, Combination; Humans; Ketoconazole; Neoplasm Recurrence, Local; Tretinoin; Urinary Bladder Neoplasms

Retinoids modulate the growth and differentiation of normal and malignant epithelial cells in vitro and in vivo. Retinoids and their analogues have been used in animal models and clinical trials of chemoprevention and superficial bladder cancer treatment. Interferons are cytokines that have antiviral, antiproliferative and immunomodulatory function. They are used in many clinical trials for the treatment of different cancers. To identify new effective agents and develop novel approaches for the chemoprevention and treatment of superficial bladder cancer we investigated the effects of a combination of retinoids and interferon alpha-2a (IFN) on growth and apoptosis in bladder cancer cell lines.. The 4 bladder cancer cell lines UM-UC-6, UM-UC-9, UM-UC-10 and UM-UC-13 were treated with 2 retinoids, namely all-trans-retinoic acid (ATRA) and 9-cis retinoic acid (9cRA), as well as with IFN or with combinations of retinoids and IFN. The ability of these agents used alone and in combination to inhibit growth, induce apoptosis and modulate gene expression was investigated. The effects of retinoids on an INF related gene were also examined.. Most bladder cancer cell lines were resistant to growth inhibition and apoptosis induction by ATRA and 9cRA, even at a high concentration. The effects of these retinoids on cell growth and apoptosis were enhanced by IFN. The combination of ATRA and IFN induced retinoic acid receptor beta, and signal transducer and activator of transcription 1 expression in 3 bladder cancer cell lines, as detected by reverse transcriptase-polymerase chain reaction and Western blot analysis. Retinoids increased IFN-related gene expression detected by microarray analysis and real-time reverse transcriptase-polymerase chain reaction.. The results demonstrate that IFN acts synergistically with ATRA and 9cRA in the growth and apoptosis of bladder cancer cells in vitro and suggest that this combination has a potential for the treatment of transitional cell carcinoma of the bladder.

Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Transitional Cell; Cell Line, Tumor; DNA-Binding Proteins; Drug Therapy, Combination; Humans; Interferon alpha-2; Interferon-alpha; Protein Array Analysis; Recombinant Proteins; STAT1 Transcription Factor; Trans-Activators; Tretinoin; Urinary Bladder Neoplasms

Superficial bladder cancer is a major target for chemoprevention. Retinoids are important modulators of epithelial differentiation and proliferation and are effective in the treatment and prevention of several epithelial cancers. One class of compounds, the retinamides, is structurally similar to other retinoids but have the added feature of being potent apoptosis inducers. Among these, fenretinide (N-[4-hydroxyphenyl]retinamide), or 4HPR, has promise for bladder cancer chemoprevention and is currently under Phase III study in this setting. In addition to 4HPR, there are several new structurally related phenylretinamides bearing hydroxyl, carboxyl, or methoxyl residues on carbons 2, 3, and 4 of the terminal phenylamine ring [designated N-(2-hydroxyphenyl)retinamide, N-(3-hydroxyphenyl)retin amide, N-(2-carboxyphenyl)retin- amide, N-(3-carboxyphenyl)retin amide, N-(4-carboxy- phenyl)retinamide, and N-(4-methoxyphenyl)retinamide, respectively]. The objective of this study was to compare the growth inhibitory and apoptotic effects of these phenylretinamides with 4HPR in human bladder transitional cell cancer-derived cell lines of varying histological grade (RT4, grade 1; UM-UC9 and UM-UC10, grade 3; and UM-UC14, grade 4) by cell counting, cell cycle fluorescence-activated cell sorter analysis and a dual stain apoptosis assay. All of the seven phenylretinamides reduced cell number, altered the cell cycle distribution, and induced apoptosis when administered at a concentration of 10 microM, which is within the pharmacologically achievable range. Although the relative potencies of the phenylretinamides varied depending on the cell line, N-(3-hydroxy phenyl)retin- amide was the most active with significantly greater growth inhibition than 4HPR in all of the four cell lines. These in vitro findings warrant further study of these novel phenylretinamides, which may have potential as preventive or therapeutic agents in transitional cell cancer.

Topics: Anticarcinogenic Agents; Antineoplastic Agents; Apoptosis; Carcinoma, Transitional Cell; Cell Division; Fenretinide; Humans; Retinoids; Tretinoin; Tumor Cells, Cultured; Urinary Bladder Neoplasms

The aim of this study was to investigate the effect of retinoic acid (RA) and its complexes with transition metals on the bladder cancer cell line EJ. Retinoic acid complexes with transition metals Cu, Co, Zn, and Ni were prepared. Cell proliferation was tested by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in the presence of RA or its complexes with transition metals Cu, Co, Zn, and Ni ¿Cu(RA)2.3H2O, Co(RA)2.3H2O, Zn(RA)2.4H2O, and Ni(RA)2.3H2O¿. Colony formation in soft agar culture, A agglutination reaction, and lactic acid dehydrogenase isoenzyme assay were performed in the cells treated with these drugs to estimate the induced differentiation. p53 or c-Ha-ras expression in drug-treated cells was assayed by ABC immunocytochemistry technique. The results demonstrate that EJ cells treated with the drugs become less confluent and tend to exhibit normal characteristics. Although RA and its complexes showed inhibition to proliferation of EJ cells at the concentrations of 10(-6) mmol/l, the inhibition induced by Ni(RA)2.3H2O was much more marked than that by RA. EJ cells were growth inhibited by RA or Ni(RA)2.3H2O from 48 to 96 h at the concentration of 10(-8) mol/l. The levels of LDH4 and LDH5 in the cells were greatly increased by RA. Nevertheless, Ni(RA)2.3H2O did not affect LDH isoenzyme in EJ cells. The number of colony formations of EJ cells in soft agar culture was decreased by RA or Ni(RA)2.3H2O. The percentage of colony formation in soft agar culture was much lower in EJ cells treated with Ni(RA)2.3H2O than with RA. The required concentration of A agglutination reaction was more increased for EJ cells treated with RA or Ni(RA)2.3H2O than for the control and was further increased in cells treated with Ni(RA)2.3H2O. Mutant p53 expression was more decreased in the EJ cells treated with RA or Ni(RA)2.3H2O than in the control. Although RA at the concentration of 10(-6) mmol/l caused lower p21 expression, Ni(RA)2.3H2O did not affect p21 expression in EJ cells. Therefore, RA and its transition metal complexes have a potential use in the treatment of bladder cancer.

Topics: Agar; Agglutination Tests; Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Differentiation; Cell Division; Cobalt; Copper; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Isoenzymes; L-Lactate Dehydrogenase; Metals; Mutation; Nickel; Proto-Oncogene Proteins p21(ras); Tretinoin; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms; Zinc

The present study examined the expression and role of the thiazolidinedione (TZD)-activated transcription factor, peroxisome proliferator-activated receptor gamma (PPARgamma), in human bladder cancers. In situ hybridization shows that PPARgamma mRNA is highly expressed in all human transitional epithelial cell cancers (TCCa's) studied (n=11). PPARgamma was also expressed in five TCCa cell lines as determined by RNase protection assays and immunoblot. Retinoid X receptor alpha (RXRalpha), a 9-cis-retinoic acid stimulated (9-cis-RA) heterodimeric partner of PPARgamma, was also co-expressed in all TCCa tissues and cell lines. Treatment of the T24 bladder cancer cells with the TZD PPARgamma agonist troglitazone, dramatically inhibited 3H-thymidine incorporation and induced cell death. Addition of the RXRalpha ligands, 9-cis-RA or LG100268, sensitized T24 bladder cancer cells to the lethal effect of troglitazone and two other PPAR- activators, ciglitazone and 15-deoxy-delta(12,14)-PGJ2 (15dPGJ(2)). Troglitazone treatment increased expression of two cyclin-dependent kinase inhibitors, p21(WAF1/CIP1) and p16(INK4), and reduced cyclin D1 expression, consistent with G1 arrest. Troglitazone also induced an endogenous PPARgamma target gene in T24 cells, adipocyte-type fatty acid binding protein (A-FABP), the expression of which correlates with bladder cancer differentiation. In situ hybridization shows that A-FABP expression is localized to normal uroepithelial cells as well as some TCCa's. Taken together, these results demonstrate that PPARgamma is expressed in human TCCa where it may play a role in regulating TCCa differentiation and survival, thereby providing a potential target for therapy of uroepithelial cancers.

Topics: Alitretinoin; Antineoplastic Agents; Apoptosis; Carcinoma, Transitional Cell; Carrier Proteins; Cell Death; Chromans; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA; DNA, Complementary; Dose-Response Relationship, Drug; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; G1 Phase; Humans; Immunoblotting; In Situ Hybridization; Ligands; Luciferases; Myelin P2 Protein; Neoplasm Proteins; Nicotinic Acids; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Ribonucleases; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Transfection; Tretinoin; Troglitazone; Tumor Cells, Cultured; Tumor Suppressor Proteins; Urinary Bladder Neoplasms

Bladder cancer cells have been shown to secrete a variety of factors that are not related to cells of urothelial origin. The histogenesis of these tumour developments is uncertain, and a variety of theories have been previously reported. In the present manuscript, we identify the factors constitutively produced by a human bladder cancer cell line (KU-19-19) that was found to produce beta human chorionic gonadotrophin (beta-hCG), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin 1alpha (IL-1alpha), interleukin 6 (IL-6) and interleukin 8 (IL-8). The cells were obtained from a case of metastatic carcinoma that was originally diagnosed to be a grade 3 (WHO classification), invasive transitional cell carcinoma of the bladder. On microscopic observation, the cultured cells exhibited an epithelial appearance with vacuole formation in their cytoplasm. Ultrastructural observations revealed relatively marked microvilli and a tight junction. Significant amounts of beta-hCG, G-CSF, GM-CSF, IL-1alpha, IL-6 and IL-8 concentrations in the supernatant from cultured cells were demonstrated by enzyme-linked immunosorbent assays, while the expression of mRNA of these marker proteins in cancer cells was also significantly exhibited by reverse transcription polymerase chain reaction (RT-PCR). In addition, the expression of G-CSF receptor and IL-6 receptor mRNA was also shown by RT-PCR. Xenograft transplantability using nude mice was observed in association with the presence of severe neutrophilia in the peripheral blood. These results indicate that this cell line appears to be an effective model for the study of transitional cell carcinoma of the bladder with multipotent differentiation potentials.

Topics: Aged; Animals; Carcinoma, Transitional Cell; Cell Differentiation; Chorionic Gonadotropin, beta Subunit, Human; Cytokines; DNA Primers; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Electron; Neoplasm Transplantation; Polymerase Chain Reaction; RNA, Messenger; Tretinoin; Tumor Cells, Cultured; Urinary Bladder Neoplasms

To study the effect of tretinoin (Tre) or retinol (Ret) on the proliferation of lymphokine-activated killer (LAK) cells in patients with transitional cell cancer of bladder and their cytolysis to bladder tumor cells.. LAK cell proliferation was assayed in the presence of either Tre or Ret by cell counting. Human transitional bladder cancer cell lines BIU-87, EJ, or bladder tumor cells (BTC) from patients with bladder cancer were used as target cells and cytotoxicity of LAK cells was determined by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.. The proliferation of LAK cells induced by interleukin-2 (IL-2) was stimulated by Tre or Ret (10-100 nmol.L-1). The cytotoxicity of LAK cells against BIU-87, EJ cells, or BTC was enhanced by pretreatment of LAK cells with Tre or Ret 10-100 nmol.L-1.. Tre or Ret enhances the proliferation and cytotoxicity of LAK cells from patients with bladder cancer. Retinoids are potential in adoptive immunotherapy of bladder cancer.

Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Division; Cytotoxicity, Immunologic; Humans; Immunotherapy, Adoptive; Killer Cells, Lymphokine-Activated; Tretinoin; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vitamin A

The aim was to establish a model of reversible radiosensitization in human tumor cell lines by all-trans retinoic acid without influencing cell cycle or differentiation.. Three human carcinoma cell lines (one bladder and two lung lines) were incubated in medium containing delipidized serum with or without varying concentrations of all-trans retinoic acid for a range of time periods, and their acute response to radiation measured by clonogenic assay. Cell phenotype was monitored using growth rates, morphology, and intermediate filament expression.. Two of the three cell lines (those in which cell kill was predominantly through reparable damage beta in control cultures) showed an increase in radiosensitivity with retinoic acid, at a concentration with no discernable effect on phenotype (10(-7) M). No significant change in alpha values was observed. The values for beta increased from 0.057 to 0.109 and from 0.039 to 0.075, corresponding to dose modification factors of 1.59 and 1.67. When retinoic acid was removed prior to irradiation, cell survival returned to control levels by 48 h.. Radiosensitization occurred at retinoic acid concentrations that did not otherwise perturb the cells; the effect may be due to inhibition of DNA repair in cells usually competent at repair. The model provides a method of altering radiosensitivity in selected cell lines without genetic mutation, which may enable investigation of DNA repair mechanisms.

Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Transitional Cell; Cell Cycle; Cell Survival; Humans; Lung Neoplasms; Phenotype; Radiation Tolerance; Time Factors; Tretinoin; Tumor Cells, Cultured; Urinary Bladder Neoplasms

The model of precancerous lesions of the bladder in rats was induced by N-butyl-(4-hydroxybutyl) nitrosamide (BBN). The animals were randomly divided into the following 3 groups: 1) given Antitumor-B (Chinese herbs); 2) given 4-ethoxycarbophenylretinamide (Retinamide); and 3) control. After treatment for 13 months the rats were killed for pathomorphological examination of the bladder. The results showed that the incidence of bladder cancer in group 1 and 2 was reduced by 90.7% (P < 0.01) and 75.0% (P < 0.01) respectively after treatment as compared with the control group. Our results provide a useful reference for clinical trial in the prevention of bladder cancer recurrence by using antitumor-B and Retinamide.

Topics: Animals; Antineoplastic Agents, Phytogenic; Butylhydroxybutylnitrosamine; Carcinoma, Transitional Cell; Drugs, Chinese Herbal; Precancerous Conditions; Rats; Rats, Wistar; Tretinoin; Urinary Bladder Neoplasms

An in vitro clonogenic assay was used to study the activity of 3 established cytotoxic drugs and 3 experimental agents against a series of 33 human transitional cell carcinomas. Strict adherence to rigid colony size criteria gave very reproducible results with the 3 cytotoxic drugs (adriamycin, mitomycin C and thiotepa) and our sensitivity curves are of the form expected on the basis of past experience with tumour cell lines. The unexplained plateau form curves which have previously led to criticism of the assay were not seen. Resistant subpopulations were found only in poorly differentiated tumours. This modified assay was then used to test 3 experimental agents for activity against transitional cell carcinoma. Sulphopentosan, DMSO and retinoic acid all proved inactive in this system.

Topics: Carcinoma, Transitional Cell; Clone Cells; Colony-Forming Units Assay; Culture Techniques; Dimethyl Sulfoxide; Doxorubicin; Drug Resistance; Humans; Methods; Mitomycin; Mitomycins; Thiotepa; Tretinoin; Urinary Bladder Neoplasms

The chemopreventive activity of two synthetic retinamides of relatively low toxicity against N-butyl-N-(4-hydroxybutyl)nitrosamine (OH-BBN)-induced urinary bladder cancer was studied in F344 rats and C57BL/6 X DBA/2 F1 mice. Female and male rats were given a total dose of either 1800 or 3200 mg OH-BBN over a period of 6 or 8 weeks, respectively. Male mice were given a total dose of either 90 or 180 mg OH-BBN over a period of 9 weeks. Seven days after the final intubation of a period of 9 weeks. Seven days after the final intubation of OH-BBN, animals were fed either a placebo diet or a diet supplemented with the following retinoids: for rats, 0.8 mmol 13-cis-retinoic acid, 2 mmol N-(ethyl)-all-trans-retinamide, or 2 mmol N-(2-hydroxyethyl)-all-trans-retinamide per kg diet; and for mice, either 0.5 or 1.0 mmol of N-(ethyl)-all-trans-retinamide or N-(2-hydroxyethyl)-all-trans-retinamide per kg diet. Animals were killed 6 months after the initial gastric intubation. In comparison to male and female rats fed placebo diets, all three retinoids reduced the incidence, number, and severity of the low-grade papillary transitional cell carcinomas of the urinary bladder. Similarly, treatment of mice with either of the two retinamides reduced the incidence of highly invasive urinary bladder carcinomas. The chemopreventive effect of the less toxic retinamides was equal to or greater than that of 13-cis-retinoic acid.

Topics: Animals; Butylhydroxybutylnitrosamine; Carcinoma, Transitional Cell; Female; Male; Mice; Neoplasms, Experimental; Nitrosamines; Rats; Tretinoin; Urinary Bladder Neoplasms

Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Humans; Neoplasm Recurrence, Local; Thiotepa; Tretinoin; Urinary Bladder Neoplasms

The effect of a delay in starting 13-cis-retinoic acid treatment on the inhibition of urinary bladder carcinoma induced by N-butyl-N-(4-hydroxybutyl)nitrosamine was studied in male Fischer 344 rats. Animals received a total p.o. dose of either 1200, 1800 or 2400 mg N-butyl-N-(4-hydroxybutyl)nitrosamine over a period of six weeks. At either one, five, and nine weeks after the last N-butyl-N-(4-hydroxybutyl)nitrosamine intubation, animals were started on a diet supplemented with 13-cis-retinoic acid (240 mg/kg of laboratory chow) or continued on laboratory chow. Animals were killed at one year after the first carcinogen intubation for histological evaluation of the bladder. Feeding of 13-cis-retinoic acid reduced the incidence, average number, and severity of transitional cell carcinomas as well as hyperplasia and cellular atypia. Furthermore, even a nine-week delay in starting the retinoid feeding did not diminish the ability of 13-cis-retinoic acid to inhibit bladder carcinogenesis.

Topics: Animals; Butylhydroxybutylnitrosamine; Carcinoma, Transitional Cell; Dose-Response Relationship, Drug; Male; Neoplasms, Experimental; Rats; Rats, Inbred F344; Time Factors; Tretinoin; Urinary Bladder Neoplasms; Vitamin A

The effect of 13-cis-retinoic acid on the induction of urinary bladder carcinoma by N-butyl-N-(4-hydroxybutyl)nitrosamine (OH-BBN) was studied in male C57BL/6 mice. Animals received a total dose of either 90 or 140 mg of OH-BBN via gastric intubations of 7.5 or 10.0 mg of OH-BBN 2 times each week for 6 or 7 weeks, respectively. Seven days after the last OH-BBN intubation, animals were fed laboratory chow diet supplemented with either 200 mg of 13-cis-retinoic acid per kg or its placebo. Animals were killed at 6 months after the first carcinogen intubation. Highly invasive squamous and transitional cell carcinomas of the urothelium were found at autopsy. In the majority of these carcinomas, invasion of the bladder muscle wall by tumor cells had occurred. At the two dose levels of OH-BBN, feeding of 13-cis-retinoic acid reduced the incidence of both carcinomas and noninvasive papillomas, as well as the extent of neoplastic development in the urinary bladder. In mice receiving the lower dose of OH-BBN, the feeding of 13-cis-retinoic acid prevented the appearance of both squamous and transitional cell carcinomas with a reduction in incidence from 33 to 0% (p less than 0.01). The results of this study indicate that 13-cis-retinoic acid reduced not only the severity of highly invasive urinary bladder carcinomas but also the incidence of such cancers.

Topics: Animals; Butylhydroxybutylnitrosamine; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Male; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Nitrosamines; Tretinoin; Urinary Bladder Neoplasms; Vitamin A

Transitional cell and squamous cell cancer of the bladder was induced in Wistar/Lewis female rats by direct instillation of N-methyl-N-nitrosourea into the bladder. Feeding of the synthetic retinoid, 13-cis-retinoid acid, inhibited the incidence and extent of bladder cancer in these rats, even when 13-cis-retinoic acid administration was begun after completion of the carcinogen treatment.

Topics: Animals; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Female; Methylnitrosourea; Neoplasms, Experimental; Rats; Tretinoin; Urinary Bladder Neoplasms; Vitamin A

Transitional cell carcinoma was induced in the bladders of male Fischer rats by 12 oral doses of the carcinogen N-butyl-N-(4-hydroxybutyl)nitrosamine. Feeding of 13-cis-retinoic acid after completion of carcinogen treatment diminished the number and severity of cancers and other proliferative lesions of the bladder.

Topics: Animals; Butylhydroxybutylnitrosamine; Carcinoma, Transitional Cell; Male; Neoplasms, Experimental; Nitrosamines; Rats; Rats, Inbred F344; Tretinoin; Urinary Bladder Neoplasms; Vitamin A